Compare OXLC & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXLC | ARDX |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 982.8M | 975.9M |
| IPO Year | 2010 | 2014 |
| Metric | OXLC | ARDX |
|---|---|---|
| Price | $9.11 | $3.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $6.00 | ★ $15.14 |
| AVG Volume (30 Days) | 714.1K | ★ 3.9M |
| Earning Date | 11-01-2023 | 04-30-2026 |
| Dividend Yield | ★ 18.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | $136.15 | $37.75 |
| Revenue Next Year | $5.51 | $34.24 |
| P/E Ratio | $7.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.01 | $3.34 |
| 52 Week High | $17.47 | $8.40 |
| Indicator | OXLC | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 24.11 |
| Support Level | $8.11 | N/A |
| Resistance Level | $9.14 | $3.92 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 10.80 | 14.53 |
Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.